Candel Therapeutics

We're presenting preclinical results on the therapeutic potential of CAN-3110 in the Ras-Raf pathway altered #melanoma model at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. Our poster will showcase CAN-3110's potent antitumor activity and immune activation in preclinical melanoma models. Learn more: https://lnkd.in/e7AgfVmA #SITC24 #CancerResearch #Immunotherapy #Melanoma

We’re attending the Society for Immunotherapy of Cancer (SITC) Annual Meeting this November! Join us as we discuss the activity of CAN-3110 in a model of #melanoma. CAN-3110 is a selectively replicating oncolytic herpes simplex virus designed to target and kill cancer cells expressing Nestin, a protein often found in aggressive cancers and associated with tumor growth.    For more details, see our press release: https://lnkd.in/eH3qq89Q    #SITC24  

We’re attending the Society for Immunotherapy of Cancer (SITC) Annual Meeting this November! Join us as we discuss the activity of CAN-3110 in a model of #melanoma. CAN-3110 is a selectively replicating oncolytic herpes simplex virus designed to target and kill cancer cells expressing Nestin, a protein often found in aggressive cancers and associated with tumor growth.    For more details, see our press release: https://lnkd.in/eH3qq89Q    #SITC24  

Over 1.3 million Americans are living with a primary or metastatic brain tumor today. Brain Tumor Awareness Week is dedicated to raising awareness about the unique challenges faced by those diagnosed with brain tumors and highlighting the urgent need for specialized responses and increased research efforts.    Learn more and get involved:  https://lnkd.in/eZYyu9ZD    #BrainTumorAwareness #CancerResearch 

Over 1.3 million Americans are living with a primary or metastatic brain tumor today. Brain Tumor Awareness Week is dedicated to raising awareness about the unique challenges faced by those diagnosed with brain tumors and highlighting the urgent need for specialized responses and increased research efforts.    Learn more and get involved:  https://lnkd.in/eZYyu9ZD    #BrainTumorAwareness #CancerResearch 

Our CSO Francesca Barone, MD, PhD, will present at the International Oncolytic Virotherapy Conference in Rotterdam. She'll discuss our enLIGHTEN™ Discovery Platform's AI-driven approach to viral immunotherapies for cancer. For more information: https://lnkd.in/e9-_V3QM #IOVC2024 #CancerResearch

We’re excited to have three presentations at the 16th Annual International Oncolytic Virotherapy Conference. We will present initial data based on our phase 1b clinical trial of multiple injections with CAN-3110 in recurrent high-grade glioma (#glioblastoma), advances based on the enLIGHTEN™ Discovery Platform, and our first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures in solid tumors. https://lnkd.in/e9-_V3QM    #IOVC2024 

Our President and CEO, Paul Peter Tak, MD PhD FMedSci, will attend the upcoming Longwood Healthcare Leaders #BostonCEO. On a panel, he’ll discuss next-gen therapeutics, highlighting Candel's innovative viral immunotherapies.    Learn more: https://lnkd.in/eehfZ2xB Longwood Fund #longwoodhealthcareleaders #CancerImmunotherapy #BiotechInnovation 

President and CEO, Paul Peter Tak, MD PhD FMedSci, shares insights on our CAN-3110 clinical program for recurrent high-grade glioma (#glioblastoma) with DocWire News. Tune in to this interview to learn more about our innovative investigational immunotherapies and how we’re striving to improve patient outcomes.    https://lnkd.in/ehPZQG4s    #CancerResearch #Immunotherapy 

Did you know that only about 15-40% of patients with advanced non-small cell lung cancer (NSCLC) respond to standard immune checkpoint inhibitor (ICI) therapy? In honor of #HealthyLungMonth, let's raise awareness about the ongoing need for innovative treatments in lung cancer. At Candel, we are conducting a clinical trial of an investigational viral immunotherapy, CAN-2409, which could potentially convert non-responders to ICI into responders. This approach has shown promising results in patients with progressive disease despite ICI therapy. Learn more about our clinical trials: https://lnkd.in/dTeQgMFm #LungCancerResearch #ClinicalTrials #CancerAwareness #NSCLC